Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Australian Stock Exchange  >  ResApp Health Limited    RAP   AU000000RAP5

RESAPP HEALTH LIMITED

(RAP)
  Report
End-of-day quote. End-of-day quote Australian Stock Exchange - 11/26
0.09 AUD   -1.10%
04/05RESAPP HEALTH : Morgans rates RAP as Add
AQ
2019RESAPP HEALTH : 2019 Letter to Shareholders
PU
2017RESAPP HEALTH : Updated Corporate Governance Policies
PU
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Resapp Health : Appendix 4E - Preliminary Final Report

08/31/2017 | 02:33am EST

Results for announcement to market

Up / Down

% Change

2017

$

2016

$

Revenue from ordinary activities

Up

147%

204,317

82,633

Loss after tax from ordinary activities

attributable to members Down 213% (10,032,750) (3,207,577)

Loss attributable to members Down 213% (10,032,750) (3,207,577)

Dividend Information Amount per share Franked Amount per share

Dividend - current reporting period Nil Nil

Dividend - previous reporting period Nil Nil

Net Tangible Asset Backing per Ordinary Share cents

Net tangible asset backing per ordinary share - current reporting

period 1.39

Net tangible asset backing per ordinary share - previous reporting

period 2.10

Commentary on the Results for the Period

During the year ended 30 June 2017, the Company increased its research and development activities. A large portion of the net loss for the current year is also made up of the valuation of options issued during the year.

The loss for the prior year is attributable to operating activities and research and development costs incurred following the acquisition of ResApp Diagnostics.

Audit

This Preliminary Final Report is based on the Annual Financial Report which is in the process of being audited.

Tony Keating Managing Director and Chief Executive Officer

Dated at Brisbane this 31st day of August 2017

PRINCIPAL ACTIVITIES

During the year, the Company continued the development and commericalisation of the ResApp technology for the purpose of providing health care solutions for respiratory disease.

REVIEW OF OPERATIONS Operational Review

US SMARTCOUGH-C Study

During the period, the Company commenced its SMARTCOUGH-C study in the United States (US). SMARTCOUGH-C is a multi-site, double blind, prospective clinical study to investigate ResAppDx for the diagnosis of respiratory disease in infants and children using cough sounds. The co-primary endpoints of the study are the diagnosis of pneumonia compared to clinical and radiologic diagnosis. Secondary endpoints are diagnosis of upper respiratory tract infection, lower respiratory involvement, croup, asthma/reactive airways disease and bronchiolitis compared with a clinical diagnosis.

On 21 October 2016, the Company announced that it is had received its first institutional review board (IRB) approval at the Cleveland Clinic for the SMARTCOUGH-C study. The Company subsequently announced that it had also received IRB approval at the Massachusetts General Hospital (MGH) on 11 November 2016 and at Baylor College of Medicine and Texas Children's Hospital on 16 November 2016.

On 9 December 2016, ResApp confirmed the initiation of its SMARTCOUGH-C study in the US.

On 10 January 2017, the Company announced that it had entered into a two-year expanded research collaboration with MGH alongside MGH's participation in ResApp's SMARTCOUGH-C study. Working together, ResApp and MGH will perform additional analysis of the SMARTCOUGH-C study data, use the SMARTCOUGH-C dataset to investigate the state of respiratory disease clinical practice today and evaluate the efficacy of ResApp's cough-based diagnostic test in additional respiratory disease indications.

On 15 March 2017, the Company provided an update on its SMARTCOUGH-C study confirming recruitment locations included multiple emergency departments, urgent care facilities and primary care offices at each of the three participating hospitals, with 478 participants having been enrolled as of 10 March 2017.

On 19 April 2017, the Company announced its intention to extend the SMARTCOUGH-C study through to the end of May and increase maximum recruitment to 1,500 patients. Enrolment in the study had progressed well across eleven recruitment locations maintained by the three participating hospitals, however the incidence of pneumonia and croup among study patients had been unseasonably low.

On 19 June 2017, the Company announced that it has completed enrolment in its SMARTCOUGH-C study with a total of 1,245 patients enrolled across the three participating hospitals, all located in the United States. With enrolment complete, the study entered the data verification phase, where clinical and radiologic adjudication were conducted for the remaining patients and final source data verification site visits performed.

Subsequent to the end of the period on 9 August 2017, the Company announced top-line data from its multi-site, double blind, prospective clinical study to investigate ResAppDx for the diagnosis of respiratory disease in infants and children using cough sounds. The predefined study endpoints were based on achieving greater than 75% for positive percent agreement (PPA) and negative percent agreement (NPA) for the diagnosis of pneumonia, croup, bronchiolitis, asthma/reactive airways disease (RAD), lower respiratory tract disease (LRTD) and upper respiratory tract infection (URTI).

In the final data review, prior to the un-blinding of the study data, ResApp identified at least two issues with the clinical data. Contrary to instructions and training, a high number of patients were treated before clinical research staff recorded their cough sounds. A high number of recordings were also found to contain a second person's cough sounds or an unacceptable amount of background noise and interference. These issues are known to affect cough sound analysis and their presence had skewed the preliminary results.

A preliminary analysis indicated that the study is unlikely to meet its predefined endpoints for diagnosis of childhood respiratory disease with the lower bound of the 95% confidence interval of both PPA and NPA with clinical diagnosis being below 75% of all diseases. The most promising result was for bronchiolitis, which achieved an 80% (95%CI 66%-91%) PPA and 95% (95%CI 94%-97%) NPA with clinical diagnosis, although due to the reduced number of bronchiolitis patients (caused by removing recordings with obvious issues) this result did not meet the predefined study endpoint.

The Company proposes completing a second US paediatric pivotal clinical study this US winter as well as continuing and completing its adult program, including its US adult pivotal study which is also set to begin this US winter.

Australian Clinical Studies

During the period, the Company continued its Australian paediatric clinical studies at Joondalup Health Campus (JHC) and Princess Margaret Hospital in Perth and its Australian adult studies at JHC and Wesley Hospital in Brisbane.

On 3 October 2016, ResApp announced further positive results from its Australian adult study. ResApp's cough sound-based algorithms achieved between 91% and 100% accuracy for distinguishing adult patients with chronic obstructive pulmonary disease (COPD), asthma or pneumonia from subjects with no discernible respiratory disease. In addition, the new analysis demonstrated accuracy of 100% for distinguishing patients with an upper respiratory tract infection (URTI) from the no respiratory disease group (not previously reported). The differential diagnosis of asthma versus COPD, pneumonia versus asthma and pneumonia versus COPD (not previously reported) was achieved at an accuracy in the range of 88% and 94%. As was found in the paediatric study, the algorithms were able to correctly detect lower respiratory tract disease in 84% of adult patients who were initially diagnosed as clear by experienced clinicians using stethoscopes but were finally diagnosed as having a lower respiratory tract disease after additional clinical testing.

On 18 August 2016, the Company announced preliminary clinical results that demonstrated the potential for measuring the severity of asthma or viral wheeze in children using cough sounds. The Company also announced that it had begun working with two lung function test laboratories, one at Joondalup Health Campus in Perth and one at the Wesley Hospital in Brisbane to record adult asthma and chronic obstructive pulmonary disease (COPD) patients' breathing and cough sounds alongside comprehensive lung function tests.

On 28 April 2017, ResApp announced that it had signed an exclusive worldwide license agreement with UniQuest for an additional diagnostic tool that complements ResApp's existing cough-based diagnostic technology. The tool is a set of machine learning algorithms that use a combination of clinical features to screen for childhood pneumonia. Unlike ResAppDx, it does not use cough sound analysis, but relies on commonly-taken measurements such as heart rate, temperature, presence of chest in-drawing or oxygen saturation.

On 22 June 2017, the Company provided an update on its Australian paediatric clinical study. A total of 1,127 children had been enrolled, and for most disease groups patient numbers had more than doubled since previous results. The dataset and machine learning algorithms were optimised to match the design of the SMARTCOUGH- C study as closely as possible. ResAppDx achieved between 90% and 100% PPA and between 89% and 96% NPA with clinical diagnosis of primary upper respiratory tract infection (i.e. with no comorbidities), croup, lower respiratory tract involvement, asthma/reactive airways disease (RAD) and bronchiolitis. For pneumonia, ResAppDx demonstrated 89% PPA and 79% NPA with clinical diagnosis. The lower NPA reflects the higher uncertainty in the current method of clinical diagnosis of pneumonia and in particular the clinical overlap between pneumonia, bronchiolitis and asthma/RAD, which can occur at the same time.

Doctors Without Borders / Médecins San Frontières (MSF)

On 15 September 2016, the Company, in partnership with UniQuest (the main commercialisation company of The University of Queensland), announced it had shipped smartphones to a leading global humanitarian organisation under the terms of a non-binding memorandum of understanding to field-test ResApp's smartphone-based respiratory disease diagnostic tool in the developing world. The Company subsequently named this humanitarian organisation partner as Doctors Without Borders/Médecins San Frontières (MSF), who are moving towards starting a clinical study of ResAppDx in a lower income rural context setting.

Corporate Review

On 9 November 2016, the Company confirmed the appointment of new auditors Grant Thornton Audit Pty Ltd replacing Greenwich & Co Audit Pty Ltd.

Subsequent to the end of the period, on 23 August 2017 the Company announced the appointed of Dr Philip Currie to its Scientific Advisory Board. Dr Currie is a cardiologist with more than 35 years in cardiology both in the US and in Australia with extensive experience in medical research, clinical cardiology and business.

Subsequent Events

As noted above, subsequent to the end of the period on 9 August 2017, the Company announced top-line data from its multi-site, double blind, prospective clinical study to investigate ResAppDx for the diagnosis of respiratory disease in infants and children using cough sounds. In the final data review, prior to the un-blinding of the study data, ResApp identified at least two issues with the clinical data. Contrary to instructions and training, a high number of patients were treated before clinical research staff recorded their cough sounds. A high number of recordings were also found to contain a second person's cough sounds or an unacceptable amount of background noise and interference. These issues are known to affect cough sound analysis and their presence had skewed the preliminary results. Preliminary analysis indicated that the SMARTCOUGH-C study is unlikely to meet its predefined endpoints for diagnosis of childhood respiratory disease with the lower bound of the 95% confidence interval of both PPA and NPA with clinical diagnosis being below 75% of all diseases.

The Company indicated that it proposes completing a second US paediatric pivotal clinical study this US winter as well as continuing and completing its adult program, including its US adult pivotal study which is also set to begin this US winter.

Except for the events noted above, no material events have occurred subsequent to the reporting date.

ResApp Health Limited published this content on 31 August 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 31 August 2017 06:32:07 UTC.


© Publicnow 2017
All news about RESAPP HEALTH LIMITED
04/05RESAPP HEALTH : Morgans rates RAP as Add
AQ
2019RESAPP HEALTH : 2019 Letter to Shareholders
PU
2017RESAPP HEALTH : Updated Corporate Governance Policies
PU
2017RESAPP HEALTH (ASX : RAP) talks study results and clinical trials
FI
2017RESAPP HEALTH : Update on Field Evaluation by Médecins Sans Frontières/Doctors W..
PU
2017RESAPP HEALTH : Update on Field Evaluation by Medecins Sans Frontieres
PU
2017RESAPP HEALTH : SMARTCOUGH-C Study and Paediatric Clinical Strategy Update
PU
2017RESAPP HEALTH : Appendix 4E - Preliminary Final Report
PU
2017RESAPP HEALTH : Dr Philip Currie Joins ResApp's Scientific Advisory Board
PU
2017RESAPP HEALTH : Dr Philip Currie Joins ResApp's Scientific Advisory Board
PU
More news
Financials
Sales 2021 2,40 M 1,77 M 1,77 M
Net income 2021 -4,90 M -3,62 M -3,62 M
Net cash 2021 3,10 M 2,29 M 2,29 M
P/E ratio 2021 -15,3x
Yield 2021 -
Capitalization 69,7 M 51,6 M 51,5 M
EV / Sales 2021 27,8x
EV / Sales 2022 5,53x
Nbr of Employees -
Free-Float 85,9%
Chart RESAPP HEALTH LIMITED
Duration : Period :
ResApp Health Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RESAPP HEALTH LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Average target price 0,21 AUD
Last Close Price 0,09 AUD
Spread / Highest target 128%
Spread / Average Target 128%
Spread / Lowest Target 128%
EPS Revisions
Managers
NameTitle
Tony Keating Chief Executive Officer, Executive Director & MD
Roger Aston Non-Executive Chairman
Udantha Abeyratne Chief Scientist
Rob Keniger Vice President-Technology
Christopher Ntoumenopoulos Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
RESAPP HEALTH LIMITED-63.27%52
FAIR ISAAC CORPORATION26.93%13 779
SOLARWINDS CORPORATION23.61%7 201
Q2 HOLDINGS, INC.41.96%6 202
THE DESCARTES SYSTEMS GROUP INC36.50%4 931
KINAXIS INC.88.06%3 906